more_reports

Smith & Nephew Expands Wound Care Portfolio in $22B Market

  ()
Smith & Nephew advances chronic wound solutions as the global market grows to $30.48B by 2030. Learn about new products, revenue trends, and investor considerations.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Melanoma Biotech Secures Nasdaq Listing via All-Share Merger

  ()
Scancell advances its iSCIB1+ melanoma program toward Phase 3 after agreeing to an all-share merger that brings Nasdaq access and up to $89 million in new financing.
Tags: Biotechnology / Pharmaceuticals

Biotech's Non-Cytotoxic Copper-Iodine Wound Platform Shows 72-Hour Antimicrobial Persistence in Lab Testing

  ()
As an aging population expands demand in the wound care market, a smaller player is taking on the one of the most established with its "chemistry-on-demand" technology.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Scancell, Neuphoria Agree to All-Share Merger

  ()
Neuphoria Therapeutics Inc. (NEUP:NASDAQ) and Scancell Holdings Plc (SCNLF:OTC; SCLP:AIM) agreed to an all-share merger, listing the combined company on Nasdaq while funding a Phase 3 melanoma trial.
Tags: Biotechnology / Pharmaceuticals

Novocure Hits Record Revenue and Raises 2026 Outlook

  ()
Novocure posts record Q2 revenue of $183.6 million and lifts full-year guidance after Optune Pax earns CE Mark approval in Europe. See the key catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

Novocure Posts Record Q2 Revenue of US$183.6M

  ()
Novocure Ltd. (NVCR:NASDAQ) posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year, and raised full-year guidance to US$710-US$725 million.
Tags: Biotechnology / Pharmaceuticals

US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead

Research Report
  ()
A full FDA clinical hold covers all studies of this hyperphagia candidate, and the company plans to unblind Phase 3 data. An analyst warned the trial "may need to be repeated in its entirety."
Tags: Biotechnology / Pharmaceuticals

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

  ()
PolyPid enters a major commercialization deal with Azurity for D-PLEX100 targeting surgical site infections, with upfront payments and milestone potential supporting retail investors watching PYPD progress toward 2027 launch.
Tags: Biotechnology / Pharmaceuticals

PolyPid, Azurity Sign US$330M Deal for D-PLEX100

  ()
PolyPid Ltd. (PYPD:NASDAQ) and Azurity Pharmaceuticals signed a deal worth up to US$330 million to commercialize D-PLEX100, an infection-prevention drug, in the U.S. and Canada.
Tags: Biotechnology / Pharmaceuticals

BioMarin Advances VOXZOGO Toward Full FDA Approval

  ()
BioMarin submits sNDA for traditional VOXZOGO approval in achondroplasia with a Feb 2027 PDUFA date backed by extensive long-term data and an expanding skeletal dysplasia market opportunity.
Tags: Biotechnology / Pharmaceuticals

Biotech Advances VOXZOGO Toward Landmark US FDA Approval

  ()
BioMarin Pharmaceuticals Inc.'s (BMRN:NASDAQ) supplemental New Drug Application seeking traditional approval for VOXZOGO (vosoritide) to treat children with the genetic bone-growth disorder achondroplasia has been accepted.
Tags: Biotechnology / Pharmaceuticals

Digital Health Platform Achieves SOC 2 Milestone in Booming Sector

  ()
Rocket Doctor AI reaches SOC 2 Type I compliance, strengthening its enterprise position as the digital health market expands rapidly with rising AI adoption.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Healthcare Platform Clears Major Security Milestone After Independent Audit

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) said its wholly owned Rocket Doctor platform achieved SOC 2 Type I compliance following an independent third-party audit of its security, privacy, and operational controls.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

  ()
Summit Therapeutics Inc. (SMMT:NASDAQ; SUMM:LON) is selling its Phase 3 antibiotic to Biossil for up to US$104.5 million in milestones, refocusing on its oncology drug ivonescimab.
Tags: Biotechnology / Pharmaceuticals

Houston ALS Biotech Coya Eyes 2028 Approval Path

  ()
Coya Therapeutics advances COYA 302 for ALS with strong analyst support and a key 2027 readout ahead. Discover the catalysts and industry trends driving this Houston biotech.
Tags: Biotechnology / Pharmaceuticals

Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target

  ()
Roth, Chardan Capital, and H.C. Wainwright have all issued "Buy" ratings on Coya Therapeutics Inc. (COYA:NASDAQ) in 2026. Read on to find out why analysts are intrigued.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

DarioHealth AI Platform Targets 10-15% Revenue Growth from Existing Clients

  ()
DarioHealth's DarioIQ AI engine is positioned to lift B2B2C recurring revenue 10-15% from current customers while the AI healthcare market expands rapidly toward hundreds of billions.
Tags: TechnologyHealthcare ServicesLife Sciences Tools & DiagnosticsArtificial Intelligence

AI Engine Delivers Engagement Gains as Recurring Revenue Outlook Climbs

  ()
DarioHealth Corp. (DRIO:NASDAQ) said its DarioIQ platform reflects the ongoing digital health rotation and AI transformation across healthcare, with broader deployment expected to increase recurring revenue from existing customers by 10% to 15%.
Tags: Life Sciences Tools & DiagnosticsHealthcare ServicesTechnologyArtificial Intelligence

Pet Odor Market Ignites BioLargo Consumer Comeback

  ()
BioLargo re-enters the booming U.S. pet odor control market with a direct-to-consumer CupriDyne brand, building on proven demand while advancing water treatment and medical technologies for retail investors.
Tags: TechnologySpecial SituationsHealthcare ServicesLife Sciences Tools & DiagnosticsCleantech

Cleantech Co. Relaunches Pet Brand Under Its Own Control

  ()
BioLargo Inc. (BLGO:OTCQX) unveils plans to reintroduce its enormously popular CupriDyne-based pet odor products to the consumer market. This time, the company says it will own the brand and do it its own way.
Tags: TechnologySpecial SituationsHealthcare ServicesLife Sciences Tools & DiagnosticsCleantech

Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.
Tags: Biotechnology / Pharmaceuticals